HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Deals

Beeline, a Bain-backed biotech, debuts with immune drugs from Bristol Myers

Equipped with $300 million, Beeline has an oral medicine for the treatment of lupus as well as other experimental drugs targeting autoimmune diseases.

By BioPharma Dive · Apr 15, 2026 · via BioPharma Dive
Beeline, a Bain-backed biotech, debuts with immune drugs from Bristol Myers

Image: BioPharma Dive

Tags
dealsformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Deals
All Deals →
In industry's latest OTC pivot, Daiichi Sankyo lines up $1.5B consumer health unit sale to beverage giant Suntory
DealsFiercePharma ↗
In industry's latest OTC pivot, Daiichi Sankyo lines up $1.5B consumer health unit sale to beverage giant Suntory
With Daiichi Sankyo’s priorities increasingly tied to its innovative medicines—and its oncology portfolio in p…
Apr 17, 2026
UCB Buys Neurona for $650M, Bets on Regenerative Medicine and Epilepsy Cell Therapy
DealsBriefing
UCB Buys Neurona for $650M, Bets on Regenerative Medicine and Epilepsy Cell Therapy
UCB’s $650M-plus purchase of Neurona Therapeutics signals a move beyond small molecules into regenerative neur…
Apr 17, 2026
Novo Nordisk Bets on OpenAI to Accelerate Drug Development
DealsBriefing
Novo Nordisk Bets on OpenAI to Accelerate Drug Development
Novo Nordisk unveiled a global AI collaboration with OpenAI, extending from drug discovery to manufacturing as…
Apr 17, 2026